AngioDynamics ANGO Increase In Placement And Evaluation Units
Increase In Placement And Evaluation Units at other companies
Other financials
Where this comes from
Reported directly by AngioDynamics in its filing.
Tagged under the XBRL concept ango:IncreaseInPlacementAndEvaluationUnits.
The official record: AngioDynamics’s 10-K, filed July 18, 2025, on SEC EDGAR. View the filing →
Ask your AI about AngioDynamics's increase in placement and evaluation units.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is AngioDynamics's increase in placement and evaluation units?
- AngioDynamics (ANGO) reported increase in placement and evaluation units of $1.43M in Q1 2025.
- How has AngioDynamics's increase in placement and evaluation units changed year-over-year?
- AngioDynamics's increase in placement and evaluation units increased by 13.9% year-over-year, from $1.25M to $1.43M.
- What is the long-term trend for AngioDynamics's increase in placement and evaluation units?
- Over 4 years (2021 to 2025), AngioDynamics's increase in placement and evaluation units has grown at a -9.5% compound annual growth rate (CAGR), from $8.52M to $5.71M.
- What does increase in placement and evaluation units mean?
- This represents capital expenditures related to the deployment of medical devices or equipment at customer sites for evaluation or long-term use. It reflects the company's strategy of placing hardware to drive recurring revenue through consumables or service contracts. High investment in these units indicates a focus on expanding the installed base to secure future market share.